Patient perceptions of cardiovascular risk, lipid management and statins in type 1 diabetes

Prim Care Diabetes. 2023 Oct;17(5):526-528. doi: 10.1016/j.pcd.2023.07.005. Epub 2023 Jul 31.

Abstract

Lipid-lowering reduces cardiovascular risk in type 1 diabetes (T1D), but dyslipidaemia remains under-recognised and under-treated. Through patient surveys, barriers to lipid management in T1D were identified, including lack of awareness of cardiovascular risk and cholesterol levels, preference for managing glycaemia over lipids, preference for lifestyle modification over pharmacotherapy, and statin side-effect concerns.

Keywords: Cardiovascular diseases; Diabetes mellitus type 1; Dyslipidaemias; Statins, Risk factors.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cardiovascular Diseases* / diagnosis
  • Cardiovascular Diseases* / epidemiology
  • Cardiovascular Diseases* / etiology
  • Diabetes Mellitus, Type 1* / diagnosis
  • Diabetes Mellitus, Type 1* / drug therapy
  • Dyslipidemias* / diagnosis
  • Dyslipidemias* / drug therapy
  • Heart Disease Risk Factors
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors* / adverse effects
  • Lipids
  • Risk Factors

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Lipids